Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
17
×
life sciences
boston blog main
national blog main
boston top stories
clinical trials
national top stories
biotech
drugs
fda
new york blog main
alnylam pharmaceuticals
new york top stories
patisiran
rna interference
san francisco blog main
akcea therapeutics
cancer
editas medicine
hereditary transthyretin amyloidosis
inotersen
onpattro
pfizer
san diego blog main
san diego top stories
san francisco top stories
tafamidis
aminolevulinic acid
broad institute
crispr
david liu
deals
financing
foundation medicine
gene editing
givosiran
licensing
roche
svb leerink
venture capital
What
medicine
17
×
fda
drug
alnylam
new
rna
gene
rnai
approval
interference
patients
pharmaceuticals
second
seek
therapeutics
ago
approved
billion
cells
crispr
data
editas
editing
filing
historic
make
making
market
morning
multiple
ok
pay
puts
recently
rest
roche
specifically
speedy
therapy
tumor
Language
unset
Current search:
boston
×
medicine
×
@xconomy.com
4 years ago
VenBio Partners Bags $394M to Back More Medicine-Making Biotechs
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
3 Changes We Should Make to Address the Gender Pay Gap in Medicine
@xconomy.com
4 years ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Digital Tools, Online Community & More: Patient Partnership Award Finalists
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M